Xenon Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA98420N1050

SecurityXENE / Xenon Pharmaceuticals Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership67,723 shares
Latest Disclosed Value $ 3,938,092
Alps Advisors Inc reports 6.98% increase in ownership of XENE / Xenon Pharmaceuticals Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 67,723 shares of Xenon Pharmaceuticals Inc. (US:XENE) valued at $3,938,092 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 63,302 shares of Xenon Pharmaceuticals Inc.. This represents a change in shares of 6.98% during the quarter. The current value of the position is $3,620,472 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 67,723 4,421 6.98 3,938 38.81 0.0185
2026-02-12 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 63,302 26,002 69.71 2,837 89.51 0.0165
2025-11-05 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 37,300 -4,080 -9.86 1,498 15.60 0.0083
2025-08-11 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 41,380 -13,952 -25.22 1,295 -30.23 0.0075
2025-04-30 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 55,332 -6,316 -10.25 1,856 -23.18 0.0108
2025-02-13 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 61,648 4,659 8.18 2,417 7.71 0.0153
2024-11-12 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 56,989 -1,864 -3.17 2,244 -2.22 0.0150
2024-08-13 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 58,853 5,653 10.63 2,295 0.17 0.0158
2024-05-14 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 53,200 2,420 4.77 2,290 -2.05 0.0162
2024-02-14 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 50,780 3,431 7.25 2,339 44.59 0.0184
2023-11-14 2023-09-30 13F XENON PHARMACEUTICALS COM 98420N105 47,349 626 1.34 1,617 -10.07 0.0134
2023-08-14 2023-06-30 13F XENON PHARMACEUTICALS COM 98420N105 46,723 5,195 12.51 1,799 21.00 0.0156
2023-05-10 2023-03-31 13F XENON PHARMACEUTICALS COM 98420N105 41,528 -843 -1.99 1,486 -11.02 0.0131
2023-02-14 2022-12-31 13F XENON PHARMACEUTICALS COM 98420N105 42,371 8,412 24.77 1,671 36.22 0.0149
2022-11-14 2022-09-30 13F XENON PHARMACEUTICALS COM 98420N105 33,959 2,461 7.81 1,226 27.97 0.0116
2022-08-15 2022-06-30 13F/A-1 XENON PHARMACEUTICALS COM 98420N105 31,498 31,498 958 0.0093
2022-08-11 2022-06-30 13F XENON PHARMACEUTICALS COM 98420N105 31,498 31,498 958 0.0092
2022-05-13 2022-03-31 13F XENON PHARMACEUTICALS COM 98420N105 0 -59,702 -100.00 0 -100.00
2022-02-09 2021-12-31 13F XENON PHARMACEUTICALS COM 98420N105 59,702 9,287 18.42 1,865 142.21 0.0210
2021-11-15 2021-09-30 13F XENON PHARMACEUTICALS COM 98420N105 50,415 -3,544 -6.57 770 -23.38 0.0074
2021-08-11 2021-06-30 13F XENON PHARMACEUTICALS COM 98420N105 53,959 -9,372 -14.80 1,005 -11.38 0.0089
2021-05-07 2021-03-31 13F XENON PHARMACEUTICALS COM 98420N105 63,331 77 0.12 1,134 16.55 0.0111
2021-02-03 2020-12-31 13F XENON PHARMACEUTICALS COM 98420N105 63,254 18,630 41.75 973 96.96 0.0110
2020-11-05 2020-09-30 13F/A-1 XENON PHARMACEUTICALS COM 98420N105 44,624 -3,080 -6.46 494 -17.39 0.0073
2020-11-04 2020-09-30 13F XENON PHARMACEUTICALS COM 98420N105 44,624 -3,080 494 6,331.2018
2020-08-05 2020-06-30 13F XENON PHARMACEUTICALS COM 98420N105 47,704 47,704 598 0.0080
2020-02-07 2019-12-31 13F XENON PHARMACEUT COMMON STOCK 98420N105 0 -51,356 -100.00 0 -100.00
2019-11-04 2019-09-30 13F XENON PHARMACEUT COMMON STOCK 98420N105 51,356 -2,532 -4.70 463 -12.81 0.0036
2019-08-07 2019-06-30 13F XENON PHARMACEUT COMMON STOCK 98420N105 53,888 -7,076 -11.61 531 -14.22 0.0039
2019-05-01 2019-03-31 13F XENON PHARMACEUT COMMON STOCK 98420N105 60,964 3,168 5.48 619 69.59 0.0044
2019-02-04 2018-12-31 13F XENON PHARMACEUT COMMON STOCK 98420N105 57,796 57,796 365 0.0028
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.